Innate Pharma (IPH) Corporate presentation summary

Strategic direction and leadership

• Focused on advancing innovative antibody-based cancer therapies targeting high unmet medical needs.

• Prioritizes investment in three lead clinical assets: IPH4502, lacutamab, and monalizumab.

• Led by an experienced management team with backgrounds at major pharmaceutical companies.

• Streamlining organization to align with strategic objectives and optimize resource allocation.

Clinical pipeline and development milestones

• IPH4502: Phase 1 ongoing for Nectin-4 ADC in solid tumors, with dose escalation data expected H1 2026.

• Lacutamab: Preparing for Phase 3 in CTCL, with FDA clearance for confirmatory trial and potential accelerated approval in Sézary syndrome.

• Monalizumab: Phase 3 PACIFIC-9 trial in NSCLC ongoing, with top-line results anticipated H2 2026.

• Multiple additional partnered and proprietary assets in preclinical and early clinical stages.

Lacutamab: clinical data and market opportunity

• Demonstrated high clinical benefit and durable responses in CTCL subtypes, including Sézary syndrome and mycosis fungoides.

• Favorable safety profile and improvements in quality of life observed in trials.

• Positioned as a potential new standard of care in 2L CTCL, with significant market expansion potential.

• Real-world data indicate higher incidence of CTCL than previously reported, supporting broader commercial opportunity.

• Peak year sales estimated up to $500m in US/EU for expanded indications.